Heparin-Induced Thrombocytopenia (HIT) Epidemiology

Key Highlights

• Heparin-induced thrombocytopenia (HIT) is a serious and potentially life-threatening immune-mediated adverse reaction caused by administering heparin, a commonly used anticoagulant medication
• Heparin-induced thrombocytopenia (HIT) is characterized by a rapid decrease in platelet count occurring 5–14 days after the initiation of heparin therapy. It is primarily caused by the formation of antibodies against the complex of platelet factor 4 (PF4) and heparin. These antibodies induce platelet activation, leading to a prothrombotic state and an increased venous and arterial thrombosis risk.
• The diagnosis of HIT is based on a combination of clinical assessment, laboratory tests, and the 4Ts scoring system. Laboratory tests include measuring platelet count, detecting anti-PF4/heparin antibodies, and functional assays to assess platelet activation. A high clinical suspicion, supported by positive laboratory findings, is essential for accurate diagnosis.
• The diagnosis of HIT is based on a combination of clinical assessment, laboratory tests, and the 4Ts scoring system. Laboratory tests include measuring platelet count, detecting anti-PF4/heparin antibodies, and functional assays to assess platelet activation. A high clinical suspicion, supported by positive laboratory findings, is essential for accurate diagnosis.
• The total diagnosed incident cases of Heparin Induced Thrombocytopenia (HIT) comprised ~217,000 cases in 2019 and are projected to reach ~262,000 cases by 2034 at a CAGR of 1.45%, accounting for the second-highest diagnosed incident cases in the 7MM.

DelveInsight’s “Heparin Induced Thrombocytopenia (HIT)– Epidemiology Forecast – 2034” report delivers an in-depth understanding of the HIT, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2021-2034

Heparin Induced Thrombocytopenia (HIT) Understanding and Diagnostic Algorithm

Heparin Induced Thrombocytopenia (HIT) Overview

Heparin is a medication and naturally occurring glycosaminoglycan; since heparins depend on antithrombin activity, they are considered anticoagulants. Heparin is a polymer of varying chain sizes. Two forms of heparin are used as pharmaceuticals: unfractionated heparin (UFH), which has not been fractionated to sequester the fraction of molecules with low molecular weight, and low molecular weight heparin (LMWH), which has undergone fractionation. Heparin is a medication commonly used to prevent blood clots; however, the immune system can trigger heparin to cause blood clots and thrombocytopenia. This condition is called HIT.

Further details related to overview are provided in the report…

Heparin Induced Thrombocytopenia (HIT) Diagnosis

Establishing HIT diagnosis in patients with complicated medical conditions can be challenging. Other causes of thrombocytopenia, such as bacterial infection, drugs other than heparin, and bone marrow disease, should be excluded, and platelet counts should recover after discontinuing heparin. Diagnosing HIT in patients who have undergone recent cardiac surgery is particularly difficult. Since, in such patients, the prevalence of heparin-dependent antibodies is high (up to 25–50%), thrombocytopenia is common, and other medications causing thrombocytopenia could be administered.

Making a rapid and confirmed diagnosis of HIT is challenging and of utmost importance. It requires the association of clinical parameters to estimate the pretest probability and laboratory assays to confirm or infirm the diagnosis. It is established by clinical evaluation and is confirmed with antibody immunoassays.

Further details related to diagnosis are provided in the report…

Explore detailed insights into emerging therapies, market trends, and key players shaping the Heparin-Induced Thrombocytopenia landscape - Heparin-Induced Thrombocytopenia Market Forecast

Heparin Induced Thrombocytopenia (HIT) Epidemiology

The Heparin Induced Thrombocytopenia (HIT) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Heparin-induced Thrombocytopenia (HIT), Total Incident Cases of Heparin-induced Thrombocytopenia (HIT) in Type-specific Heparin exposure, Age-specific Cases of Heparin-induced Thrombocytopenia (HIT), Total Cases of Thrombosis in Heparin-induced Thrombocytopenia (HIT)  covering the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2021 to 2034.

• The total diagnosed incident cases of Heparin Induced Thrombocytopenia (HIT) comprised ~217,000 cases in 2019 and are projected to reach ~262,000 cases by 2034 at a CAGR of 1.45%, accounting for the second-highest diagnosed incident cases in the 7MM.
• In 2019, the total incident cases of Heparin Induced Thrombocytopenia (HIT) in Type-Specific Heparin exposure in the United States were estimated to be ~105,100 and ~6,000 cases for UFW and LMWH. These cases are expected to reach ~123,000 and ~7,200 cases for UFW and LMWH by 2034.
• In 2019, there were ~1,500, ~27,300 , and ~83,000 cases of Heparin Induced Thrombocytopenia (HIT) in the United States, in 19 years and below, 20 years to 59 years and 60 years and above, respectively.These cases  are expected to reach in the forecast period.
• In 2019, the total cases of Thrombosis in Heparin Induced Thrombocytopenia (HIT) were ~ 64,000 cases, which were expected to reach ~78,000 cases by 2034, in the United States.

Scope of the Report

• The report covers a segment of key events, an executive summary, and a descriptive overview of Heparin Induced Thrombocytopenia (HIT), explaining its etiology, risk factors, pathophysiology, and diagnosis.
• Comprehensive insight into the country-wise epidemiology segments and forecasts, the future growth potential of diagnosis rate, and insights on disease progression have been provided.
• Patient stratification based on type and severity is an inclusion
• A detailed review of current challenges in establishing diagnosis

Heparin Induced Thrombocytopenia (HIT) Report Insights

• Total Incident Cases of Heparin-induced Thrombocytopenia (HIT),
• Total Incident Cases of Heparin-induced Thrombocytopenia (HIT) in Type-specific Heparin exposure
• Age-specific Cases of Heparin-induced Thrombocytopenia (HIT)
• Total Cases of Thrombosis in Heparin-induced Thrombocytopenia (HIT)

Heparin Induced Thrombocytopenia (HIT) Report Key Strengths

• 10 year Forecast
• The 7MM Coverage
• Heparin Induced Thrombocytopenia (HIT) Epidemiology Segmentation

Heparin Induced Thrombocytopenia (HIT)Report Assessment

• Epidemiology Segmentation
• Current Diagnostic Practices

Key Questions

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of Heparin Induced Thrombocytopenia (HIT)? What will be the growth opportunities across the 7MM with respect to the patient population of Heparin Induced Thrombocytopenia (HIT)?
• What is the historical and forecasted Heparin Induced Thrombocytopenia (HIT) patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Which type is the largest contributor to the Heparin Induced Thrombocytopenia (HIT) patient pool?
• Which severity has the most number of cases of Heparin Induced Thrombocytopenia (HIT) in the 7MM?

Reasons to Buy

• Insights on disease burden, details regarding diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the change in Heparin Induced Thrombocytopenia (HIT) cases in varying geographies over the coming years.
• Detailed overview on type-specific, severity-specific, and treated cases of Heparin Induced Thrombocytopenia (HIT) is included.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the treatment-eligible patient pool.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.